- NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
- NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
- NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
- NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
- NextCure Provides Business Update and Reports Full Year 2023 Financial Results
- NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
- NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
- NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
- NextCure Provides Year-End Clinical Pipeline Updates
- NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
More ▼
Key statistics
As of last trade, NextCure Inc (NXTC:NSQ) traded at 1.42, 44.90% above the 52 week low of 0.98 set on Oct 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.40 |
---|---|
High | 1.44 |
Low | 1.40 |
Bid | 1.42 |
Offer | 1.45 |
Previous close | 1.44 |
Average volume | 99.18k |
---|---|
Shares outstanding | 27.90m |
Free float | 25.43m |
P/E (TTM) | -- |
Market cap | 40.18m USD |
EPS (TTM) | -2.25 USD |
Data delayed at least 15 minutes, as of Apr 25 2024 14:49 BST.
More ▼